Novo Nordisk's new strategy depends on rebuilding investor trust, CEO says

Novo Nordisk's chief executive says the company is ready to expand its ambitions once more, even as investors remain skeptical about the drugmaker's new strategic direction.

CEO Mike Doustdar told CNBC that the company has reached a point where it can again broaden its scope, following a period in which Novo Nordisk faced pressure over its performance and strategic direction.

Despite the CEO's confidence, investor sentiment toward the company has remained cautious. Novo Nordisk, long known for its dominance in the diabetes and obesity drug markets, has faced increased competition and scrutiny in recent periods, contributing to what the report describes as investor backlash.

Doustdar's comments suggest that rebuilding trust with shareholders and the broader market will be a central challenge as the company works to execute its next phase of growth. The report does not specify the particular initiatives or products at the center of the new strategy.

It remains to be seen how markets will respond as Novo Nordisk moves forward with its plans, with investor confidence likely to hinge on the company's ability to deliver on its stated ambitions in the coming periods.